This company has been acquired
Forma Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
Key information
-53.24%
Earnings growth rate
40.85%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | n/a |
| Return on equity | -45.88% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30
Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11
Aug 05We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Mar 04We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Nov 20Here's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
Aug 13We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Needs To Drive Business Growth Carefully
Apr 18What Type Of Shareholders Own The Most Number of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Shares?
Jan 03Revenue & Expenses Breakdown
How Forma Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -190 | 53 | 11 |
| 31 Mar 22 | 0 | -181 | 52 | 0 |
| 31 Dec 21 | 0 | -173 | 48 | 0 |
| 30 Sep 21 | 0 | -151 | 43 | 54 |
| 30 Jun 21 | 0 | -136 | 38 | 54 |
| 31 Mar 21 | 0 | -119 | 32 | 0 |
| 31 Dec 20 | 0 | -74 | 31 | 0 |
| 30 Sep 20 | 7 | -74 | 30 | 0 |
| 30 Jun 20 | 11 | -78 | 29 | 0 |
| 31 Mar 20 | 29 | -61 | 28 | 0 |
| 31 Dec 19 | 101 | -53 | 24 | 0 |
| 31 Dec 18 | 164 | 0 | 22 | 0 |
Quality Earnings: FMTX is currently unprofitable.
Growing Profit Margin: FMTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FMTX is unprofitable, and losses have increased over the past 5 years at a rate of 53.2% per year.
Accelerating Growth: Unable to compare FMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: FMTX has a negative Return on Equity (-45.88%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/10/16 23:19 |
| End of Day Share Price | 2022/10/13 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Forma Therapeutics Holdings, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alethia Young | Cantor Fitzgerald & Co. |
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Tiago Fauth | Credit Suisse |